Business ❯ Finance ❯ Investments ❯ Biotechnology

Clinical Trials

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

Plaintiffs say the company misrepresented the promise of nimacimab after a trial update reported the primary goal was not met.

Stories older than 24h

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Skye Bioscience Investors Pressed to Seek Lead Role After Class Action Filing

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in SDNY Securities Case